SCHEMBL1770973

SCHEMBL1770973

COc1cc2c(cc1-c1ccccc1)CCN2CCNC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 6/20 0.47
PDCD1 Q15116 3/20 0.47
CD274 Q9NZQ7 3/20 0.47
MTNR1B P49286 5/20 0.45
CYP3A4 P08684 2/20 0.43
CYP19A1 P11511 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
DRD3 P35462 5/20 0.41
FAAH O00519 1/20 0.41
DRD2 P14416 4/20 0.41
DRD4 P21917 4/20 0.41
DRD1 P21728 3/20 0.41
HTR1A P08908 2/20 0.41
ADRA2A P08913 2/20 0.41
DRD5 P21918 2/20 0.41
HTR2A P28223 2/20 0.41
ADRA1A P35348 2/20 0.41
HTR7 P34969 1/20 0.41
REN P00797 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1770307 0.90 MTNR1A (0.47) MTNR1AMTNR1BCYP3A4CYP19A1CYP11B1
SCHEMBL1770654 0.83 MTNR1A (0.46) MTNR1AMTNR1BDRD4HTR2A
SCHEMBL1770605 0.76 MTNR1A (0.55) MTNR1AMTNR1B
SCHEMBL6287541 0.72 PDE4A (0.40) DRD3DRD2DRD4
SCHEMBL12598196 0.72 MTNR1A (0.53) MTNR1AMTNR1BCYP3A4DRD3DRD2
SCHEMBL1770499 0.71 MTNR1A (0.50) MTNR1AMTNR1BCYP3A4REN
SCHEMBL1771027 0.70 MTNR1B (0.52) MTNR1AMTNR1BCYP3A4REN
SCHEMBL12598202 0.70 MTNR1A (0.48) MTNR1AMTNR1BCYP3A4HTR2AREN
SCHEMBL8302626 0.70 HDAC1 (0.54) MTNR1AMTNR1BCYP3A4REN
SCHEMBL1770990 0.69 MTNR1A (0.53) MTNR1AMTNR1BCYP3A4REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112148-A1 INDOLINE COMPOUNDS FERRER INTERNACIONAL S.A. 2011-05-12 US claimed
EP-2203423-A1 INDOLINE COMPOUNDS Ferrer Internacional, S.A. (ES) 2010-07-07 EP claimed
WO-2009053440-A1 INDOLINE COMPOUNDS FERRER INTERNACIONAL S.A. (ES) 2009-04-30 WO claimed
US-20110112148-A1 INDOLINE COMPOUNDS FERRER INTERNACIONAL S.A. 2011-05-12 US disclosed
EP-2203423-A1 INDOLINE COMPOUNDS Ferrer Internacional, S.A. (ES) 2010-07-07 EP disclosed
WO-2009053440-A1 INDOLINE COMPOUNDS FERRER INTERNACIONAL S.A. (ES) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112148-A1 INDOLINE COMPOUNDS MTNR1A, MTNR1B, TPH2 MTNR1A 1/4885PDCD1 3297/4885CD274 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.